Navigation Links
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Date:12/11/2007

om management through periodic blood transfusions, non-specific immunosuppressive therapy and, infrequently, bone marrow transplantations -- a procedure that carries considerable mortality risk. (4,12)

About Soliris

Soliris was approved in March 2007 by the U.S. Food and Drug Administration (FDA) as the first treatment for PNH, a rare, debilitating and life-threatening blood disorder defined by hemolysis, or the destruction of red blood cells. In June 2007, the European Commission (EC) also approved the use of Soliris for the treatment of patients with PNH. Soliris is the first therapy approved in Europe for the treatment of PNH and was the first medicinal product to receive EC approval under the EMEA Accelerated Assessment Procedure.

Important Safety Information

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, nasopharyngitis (a runny nose), back pain and nausea. Treatment with Soliris should not alter anticoagulant management because the effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established.

The U.S. product label for Soliris also includes a boxed warning: "Soliris increases the risk of meningococcal infections. Vaccinate patients with a meningococcal vaccine at least two weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use. Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary." During clinical studies, two out of 196 vaccinated PNH patients treated with Soliris experienced a serious meningococcal infection.

Prior to beginning Soliris therapy, all patients and their prescribing physicians are enrolled in the Soliris Safety Registry which is part of a special risk management program that involves initial and continuing education and long-term monitoring for
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... ), the leading source of health information, ... on the new National Action Plan ... interview, President Obama emphasized the urgency and ... impact on national and global health.    ...
(Date:3/26/2015)... - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... therapies for cardiovascular disease and overall health, announced that ... of the Corporation (the "Common Shares"). The Common Shares ... 5 th , 2014 to March 4 th , ... on or before April 1, 2015. Interest on the ...
(Date:3/26/2015)... "Whether it,s our family, our friends, all ... In a single sentence, Dr. Anthony Coyle , ... Centers for Therapeutic Innovation (CTI), sums up ... America,s biopharmaceutical companies. CTI,s unique model ... foundations and the National Institutes of Health (NIH) to ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... , BOZEMAN, Mont., Sept 8 ... its third human clinical trial of its norovirus vaccine. ... with LigoCyte,s investigational, nasally-delivered, dry powder vaccine in healthy adults. ... of norovirus infection by including a live virus challenge of ...
... , MORGANTON, W.Va., Sept. 4 People with chronic ... and depression than people treated conventionally for back pain, a West ... , , The three-year, $400,000 study, published in ... pain and improved function in the group that did yoga postures ...
Cached Medicine Technology:LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge 2LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge 3Yoga Benefits Back-Pain Patients 2
(Date:3/28/2015)... March 28, 2015 Take a bite ... kicks into action. Acids tumble into the stomach, ready ... faulty valve-like structure lets these acids run amok, triggering ... extremely common symptom. More than 60 million Americans have ... examine where heartburn starts, and how it can be ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Thousands ... devices manufactured by C.R. Bard, Inc. continue to ... U.S. District Court, Southern District of West Virginia, ... serving on the Plaintiffs’ Steering Committee. According ... has granted certain defendants named in those lawsuits ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New ... recently commemorated its three-year anniversary of being the only ... to 24-hour urgent care, Emergency Medical Care offers its ... time, Emergency Medical Care’s Urgent Care NYC ... eye injuries, ear infections, fevers, insect bites, burns, animal ...
(Date:3/28/2015)... New York, NY (PRWEB) March 28, 2015 ... 2015 highlighted a problem which could prove critical to ... Why system testing, a critical aspect of data security, ... payment card industry data security report, every major category ... vulnerability scanning and penetration testing. “With all the craziness ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Pitching speed, player’s ... history of shoulder and elbow injuries, according to new research ... ( AOSSM ) Specialty Day. , “Our findings indicate that ... 20% increase in likelihood of a history of injury, a ... a 12% increase likelihood of a history of injury, and ...
Breaking Medicine News(10 mins):Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2
... for Brain Research in Frankfurt and at The Field Museum ... fruit bats (flying foxes) possess cones in addition to rods. ... cells, the cones for daylight vision and colour vision, and ... bats were traditionally believed to possess only rods. Hence, fruit ...
... years or more of oral steroid treatment decreases the risk ... effects were found regardless of when in the course of ... effects were not observed if the steroids were taken for ... cons of corticosteroid treatment in rheumatoid arthritis have been a ...
... an overhaul in the process used to inspect and ... ,Last fall, grocers and shoppers were in a panic ... contaminated bagged spinach. Nationwide there were 204 illnesses, 104 ... ,The FDA concluded it could not definitively determine how ...
... Ginza district Friday as they urged a boycott of ... ,Walking arm-in-arm, three women walked up to the ... wearing nothing but a banner reading: "The naked truth: ... of the protest by People for the Ethical Treatment ...
... of the public health system in the US keeps tumbling ... stated that adults// with serious mental illness and treated in ... ,The gap has widened since the early '90s ... 15 years. ,"We're going in the wrong direction ...
... headway in the development of an investigative blood test ... complications in the bone marrow, leading to life threatening ... Medical Research Institute (MMRI) and Sydney's West mead Hospital ... blood test to detect such tendencies. ...
Cached Medicine News:Health News:Research on Fruit Bats 2Health News:Research on Fruit Bats 3Health News:Long-term Oral Steroid Therapy Decreases Lymphoma Risk in Rheumatoid Arthritis 2Health News:FDAs Failure Urges It to Reassess Its Policies 2Health News:Major Mental Disorders Cut Life Span by Ten to Fifteen Years 2
... Endo-Surgery provides clip appliers in 10mm and ... appliers provide precise clip placement., ,The ... These preloaded, single-trigger instruments are designed to ... a 5mm trocar, through a 5mm reducer ...
... and IMMULITE 1000 assays are ... IMMULITE and IMMULITE 1000, continuous ... offer simplicity in both design ... be found in a wide ...
The C-Reactive Protein (CRP) assay is used for the quantitative analysis of C-reactive protein in human serum and plasma. Kit is for use with the Abbot Laboratories Aeroset, ARCHITECT c8000 or ARCHI...
... new windows for the laboratory in flexibility, ... move from one function to another. You ... and add a new patient record simultaneously. ... track of all the open functions and ...
Medicine Products: